A Multiple Center, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients with Refractory Malignancies.

Trial Profile

A Multiple Center, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients with Refractory Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jan 2014

At a glance

  • Drugs IRX 4204 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Oct 2011 Io Therapeutics reports that it has completed a phase I/II trial of IRX 4204 in patients with solid tumours.
    • 06 Oct 2011 Status changed from discontinued to completed.
    • 21 Oct 2010 Actual end date changed from Feb 2010 to Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top